Articles from Endospan

Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years.

Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS® Aortic Arch Stent Graft.

Endospan, a privately held company pioneering solutions for the endovascular repair of aortic arch disease, today announced the one-year results of their TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® Aortic Arch Stent-Graft System presented during the Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans.

Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) clinical study evaluating the NEXUS® Aortic Arch Stent-Graft System. The data were presented during the late-breaking trial session at the American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle.

Endospan, a pioneer in endovascular solutions for the Aortic Arch, today announced the completion of enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study for the NEXUS® Aortic Arch Stent Graft. The study is evaluating the safety and efficacy of the device for the treatment of aortic arch disease.

Endospan is a pioneer in off-the-shelf endovascular repair of aortic arch disease. As a notice of availability to educate potential referring physicians about the TRIOMPHE study, Endospan shared the 30-day results of the first 22 patients enrolled in the TRIOMPHE IDE study in a Late-Breaking presentation at the 60th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas this past weekend. TRIOMPHE is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS® in treating thoracic aortic lesions involving the aortic arch. The study will enroll 110 patients at up to 31 sites.

Endospan, a pioneer in endovascular repair of aortic arch disease, announces the initial experience with its custom-made NEXUS DUO™ Aortic Arch Stent Graft System. Prof. Th. Bisdas, from the Athens Medical Centre, presented the multicentric European experience of the first ten patients treated with NEXUS DUO at the Leipzig Interventional Course (LINC) on June 8th, 2023.

Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces publication a head-of-print in the Annals of Surgery of the “NEXUS Arch Multicenter Study Evaluating the Initial Experience with a Novel Aortic Arch Stent Graft System” by Planer et al.